Aleix Prat: TNBC-DX – new genomic profiling tool for the treatment of early-stage triple-negative breast cancer (TNBC)
Aleix Prat, Director of Cancer Institute and Blood Disorders at Clinical Hospital of Barcelona, shared on LinkedIn:
“Excited to share that yesterday we submitted our article for publication on the development and validation of TNBC-DX, a new genomic profiling tool for the treatment of early-stage triple-negative breast cancer (TNBC).
The validation of the test was possible thanks to our partnership with Dr. Miguel Martin, Dr. Oleg Gluz, and Dr. Nadia Harbeck.
The data will be presented at ESMO 24 in Barcelona!
With TNBC-DX, REVEAL GENOMICS, S.L. will have a 2nd product in early-stage breast cancer, ensuring genomic profiling across TNBC and HER2+.
Both tests share similarities as they unlock the potential of the patient´s immune system and their tumor characteristics.”
Source: Aleix Prat/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023